Drugs / Daphnetin
Daphnetin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06329167 | Mar 2024 → Jul 2025 | lymphedema | The First Hospital of Jilin University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07495397 | Nov 2025 → Jun 2028 expected | malignant epithelial tumor of ovary | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| — | NCT06507488 | Jul 2025 overdue | cerebrovascular disorder | First People's Hospital of Shenyang | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daphnetin | “Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage...” NCT07495397 ↗ |
| Known as | 7,8-dihydroxycoumarin | “7,8-dihydroxycoumarin” NCT06507488 ↗ |
| Known as | Daphnetin Capsules | “Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage...” NCT07495397 ↗ |
| Known as | NSC-633563 | ChEMBL registry synonym — accepted as the source's own label CHEMBL244948 ↗ |
| Known as | ZuShiMaJiaSu | “Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .” NCT06507488 ↗ |
| Modality | Small molecule | “Daphnetin, a coumarin derivative” NCT06507488 ↗ |
| Route | Oral | “Participants will take Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) orally” NCT06329167 ↗ |